vs

Side-by-side financial comparison of Gorilla Technology Group Inc. (GRRR) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Gorilla Technology Group Inc. is the larger business by last-quarter revenue ($39.3M vs $35.5M, roughly 1.1× RECURSION PHARMACEUTICALS, INC.). Gorilla Technology Group Inc. runs the higher net margin — -21.6% vs -304.2%, a 282.6% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 90.2%). Gorilla Technology Group Inc. produced more free cash flow last quarter ($-12.8M vs $-47.3M).

Gorilla Technology Group Inc. is a global AI technology solutions provider specializing in intelligent video analytics, smart city platforms, and cybersecurity products. It caters to government agencies, enterprise clients, and commercial partners across Asia Pacific, North America, and Europe, delivering scalable tools to boost operational efficiency and security for diverse industry use cases.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

GRRR vs RXRX — Head-to-Head

Bigger by revenue
GRRR
GRRR
1.1× larger
GRRR
$39.3M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+591.5% gap
RXRX
681.7%
90.2%
GRRR
Higher net margin
GRRR
GRRR
282.6% more per $
GRRR
-21.6%
-304.2%
RXRX
More free cash flow
GRRR
GRRR
$34.5M more FCF
GRRR
$-12.8M
$-47.3M
RXRX

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
GRRR
GRRR
RXRX
RXRX
Revenue
$39.3M
$35.5M
Net Profit
$-8.5M
$-108.1M
Gross Margin
34.2%
59.8%
Operating Margin
-23.1%
-304.8%
Net Margin
-21.6%
-304.2%
Revenue YoY
90.2%
681.7%
Net Profit YoY
-627.6%
39.6%
EPS (diluted)
$-0.43
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GRRR
GRRR
RXRX
RXRX
Q4 25
$35.5M
Q3 25
$5.2M
Q2 25
$39.3M
$19.2M
Q1 25
$14.7M
Q4 24
$4.5M
Q3 24
$26.1M
Q2 24
$20.7M
$14.4M
Q1 24
$13.8M
Net Profit
GRRR
GRRR
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$-162.3M
Q2 25
$-8.5M
$-171.9M
Q1 25
$-202.5M
Q4 24
$-178.9M
Q3 24
$-95.8M
Q2 24
$1.6M
$-97.5M
Q1 24
$-91.4M
Gross Margin
GRRR
GRRR
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
34.2%
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
85.5%
36.2%
Q1 24
19.1%
Operating Margin
GRRR
GRRR
RXRX
RXRX
Q4 25
-304.8%
Q3 25
-3327.6%
Q2 25
-23.1%
-916.8%
Q1 25
-1297.9%
Q4 24
-4042.4%
Q3 24
-377.1%
Q2 24
8.6%
-697.4%
Q1 24
-698.4%
Net Margin
GRRR
GRRR
RXRX
RXRX
Q4 25
-304.2%
Q3 25
-3135.3%
Q2 25
-21.6%
-894.2%
Q1 25
-1373.3%
Q4 24
-3935.5%
Q3 24
-367.5%
Q2 24
7.8%
-676.6%
Q1 24
-662.4%
EPS (diluted)
GRRR
GRRR
RXRX
RXRX
Q4 25
$-0.17
Q3 25
$-0.36
Q2 25
$-0.43
$-0.41
Q1 25
$-0.50
Q4 24
$-0.56
Q3 24
$-0.34
Q2 24
$0.15
$-0.40
Q1 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GRRR
GRRR
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$10.1M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$98.2M
$1.1B
Total Assets
$162.7M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GRRR
GRRR
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$10.1M
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$11.2M
$474.3M
Q1 24
$296.3M
Total Debt
GRRR
GRRR
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$7.4M
$22.9M
Q1 24
Stockholders' Equity
GRRR
GRRR
RXRX
RXRX
Q4 25
$1.1B
Q3 25
$1.0B
Q2 25
$98.2M
$919.1M
Q1 25
$933.9M
Q4 24
$1.0B
Q3 24
$524.6M
Q2 24
$72.1M
$584.4M
Q1 24
$401.2M
Total Assets
GRRR
GRRR
RXRX
RXRX
Q4 25
$1.5B
Q3 25
$1.4B
Q2 25
$162.7M
$1.3B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$726.5M
Q2 24
$133.1M
$775.9M
Q1 24
$557.8M
Debt / Equity
GRRR
GRRR
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.10×
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GRRR
GRRR
RXRX
RXRX
Operating Cash FlowLast quarter
$-12.5M
$-46.1M
Free Cash FlowOCF − Capex
$-12.8M
$-47.3M
FCF MarginFCF / Revenue
-32.7%
-133.1%
Capex IntensityCapex / Revenue
0.8%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GRRR
GRRR
RXRX
RXRX
Q4 25
$-46.1M
Q3 25
$-117.4M
Q2 25
$-12.5M
$-76.4M
Q1 25
$-132.0M
Q4 24
$-115.4M
Q3 24
$-59.2M
Q2 24
$-11.3M
$-82.2M
Q1 24
$-102.3M
Free Cash Flow
GRRR
GRRR
RXRX
RXRX
Q4 25
$-47.3M
Q3 25
$-117.6M
Q2 25
$-12.8M
$-79.6M
Q1 25
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-11.6M
$-83.4M
Q1 24
$-109.0M
FCF Margin
GRRR
GRRR
RXRX
RXRX
Q4 25
-133.1%
Q3 25
-2272.5%
Q2 25
-32.7%
-413.9%
Q1 25
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-56.2%
-578.5%
Q1 24
-789.9%
Capex Intensity
GRRR
GRRR
RXRX
RXRX
Q4 25
3.5%
Q3 25
4.7%
Q2 25
0.8%
16.4%
Q1 25
12.4%
Q4 24
28.6%
Q3 24
17.5%
Q2 24
1.8%
8.2%
Q1 24
48.2%
Cash Conversion
GRRR
GRRR
RXRX
RXRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-6.99×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons